title: Polysaccharide surface modified Fe3O4 nanoparticles for camptothecin loading and release.
abstract: Fe(3)O(4) nanoparticles were stabilized using different functional polysaccharides, such as chitosan (CS), O-carboxymethylchitosan (OCMCS) and (N-succinyl-O-carboxymethylchitosan (NSOCMCS) to improve their bioactivity. The release profile and the in vitro cancer cell inhibition activity of camptothecin (CPT) loaded polysaccharide modified Fe(3)O(4) nanoparticles were systematically studies. The particle size and size distribution of CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles were found to be strongly dependent on polysaccharide character. Such polysaccharide character could also affect CPT adsorption efficiency, CPT release behavior and bovine serum albumin (BSA) unspecific binding capacity. After 24 h incubation of 7721 cancer cells with CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles, significant changes in cell morphology could be discernible from phase contrast microscopy. Cytotoxicity assay showed these polysaccharide modified Fe(3)O(4) nanoparticles did not exhibit noteworthy cytotoxicity against 7721, however, the in vitro inhibition rate of CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles against 7721 liver cancer cell increased significantly in comparison with that of CPT-free drug.
authors.affiliation: College of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou 225002, PR China. apzhu@yzu.edu.cn
authors.forename: Aiping
authors.initials: A
authors.lastname: Zhu
authors.forename: Lanhua
authors.initials: L
authors.lastname: Yuan
authors.forename: Wenjie
authors.initials: W
authors.lastname: Jin
authors.forename: Sheng
authors.initials: S
authors.lastname: Dai
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Wang
authors.forename: Zhengfeng
authors.initials: Z
authors.lastname: Xue
authors.forename: Aijian
authors.initials: A
authors.lastname: Qin
mesh_terms: D000327:Adsorption / Q000187:drug effects; D000818:Animals; D002166:Camptothecin / Q000494:pharmacology*; D002417:Cattle; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008113:Liver Neoplasms / Q000473:pathology; D008858:Microscopy, Phase-Contrast; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D011134:Polysaccharides / Q000737:chemistry*; D012710:Serum Albumin, Bovine / Q000378:metabolism; D013499:Surface Properties / Q000187:drug effects
chemical_list: D004337:Drug Carriers; D005290:Ferric Compounds; D011134:Polysaccharides; C000499:ferric oxide; D012710:Serum Albumin, Bovine; D002166:Camptothecin